The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
PAK proteins and YAP-1 signalling downstream of integrin beta-1 in myofibroblasts promote liver fibrosis
Open accessAbstract
Fibrosis due to extracellular matrix (ECM) secretion from myofibroblasts complicates many chronic liver diseases causing scarring and organ failure. Integrin-dependent interaction with scar ECM promotes pro-fibrotic features. However, the pathological intracellular mechanism in liver myofibroblasts is not completely understood, and further insight could enable therapeutic efforts to reverse fibrosis. Here, we show that integrin beta-1, capable of binding integrin alpha-11, regulates the pro-fibrotic phenotype of myofibroblasts. Integrin beta-1 expression is upregulated in pro-fibrotic myofibroblasts in vivo and is required in vitro for production of fibrotic ECM components, myofibroblast proliferation, migration and contraction. Serine/threonine-protein kinase proteins, also known as P21-activated kinase (PAK), and the mechanosensitive factor, Yes-associated protein 1 (YAP-1) are core mediators of pro-fibrotic integrin beta-1 signalling, with YAP-1 capable of perpetuating integrin beta-1 expression. Pharmacological inhibition of either pathway in vivo attenuates liver fibrosis. PAK protein inhibition, in particular, markedly inactivates the pro-fibrotic myofibroblast phenotype, limits scarring from different hepatic insults and represents a new tractable therapeutic target for treating liver fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hynes (2002) · doi:10.1016/s0092-8674(02)00971-6 · Cited by 8,606
Role of YAP/TAZ in mechanotransduction
Dupont, S., Morsut, L., Aragona, M., Enzo, E., Giulitti, S., Cordenonsi, M., Zanconato, F., Le Digabel, J., Forcato, M., Bicciato, S., et al. (2011) · Nature · doi:10.1038/nature10137 · Cited by 5,979
Zhao, B., Wei, X., Li, W., Udan, R. S., Yang, Q., Kim, J., Xie, J., Ikenoue, T., Yu, J., Li, L., et al. (2007) · Genes & Development · doi:10.1101/gad.1602907 · Cited by 3,092
Calvo, F., Ege, N., Grande-Garcia, A., Hooper, S., Jenkins, R. P., Chaudhry, S. I., Harrington, K., Williamson, P., Moeendarbary, E., Charras, G., et al. (2013) · Nature Cell Biology · doi:10.1038/ncb2756 · Cited by 1,478
Mederacke, I., Hsu, C. C., Troeger, J. S., Huebener, P., Mu, X., Dapito, D. H., Pradere, J.-P., & Schwabe, R. F. (2013) · Nature Communications · doi:10.1038/ncomms3823 · Cited by 1,443
Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis
Mokdad, A. A., Lopez, A. D., Shahraz, S., Lozano, R., Mokdad, A. H., Stanaway, J., Murray, C. J., & Naghavi, M. (2014) · BMC Medicine · doi:10.1186/s12916-014-0145-y · Cited by 1,129
Henderson, N. C., Arnold, T. D., Katamura, Y., Giacomini, M. M., Rodriguez, J. D., McCarty, J. H., Pellicoro, A., Raschperger, E., Betsholtz, C., Ruminski, P. G., et al. (2013) · Nature Medicine · doi:10.1038/nm.3282 · Cited by 866
Self-citationTherapy for Fibrotic Diseases: Nearing the Starting Line
Friedman, S. L., Sheppard, D., Duffield, J. S., & Violette, S. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3004700 · Cited by 655
Self-citationClinical evidence for the regression of liver fibrosis
Ellis, E. L., & Mann, D. A. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.09.024 · Cited by 411
The Hippo pathway effector YAP controls mouse hepatic stellate cell activation
Mannaerts, I., Leite, S. B., Verhulst, S., Claerhout, S., Eysackers, N., Thoen, L. F. R., Hoorens, A., Reynaert, H., Halder, G., & van Grunsven, L. A. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.04.011 · Cited by 410
Cited by
Mechanisms of hepatic stellate cell activation
Tsuchida, T., & Friedman, S. L. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.38 · Cited by 2,909
Self-citationMechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002
Self-citationHepatic stellate cells as key target in liver fibrosis
Higashi, T., Friedman, S. L., & Hoshida, Y. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.007 · Cited by 1,485
Self-citationYAP/TAZ upstream signals and downstream responses
Totaro, A., Panciera, T., & Piccolo, S. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0142-z · Cited by 1,086
Wound healing, fibroblast heterogeneity, and fibrosis
Talbott, H. E., Mascharak, S., Griffin, M., Wan, D. C., & Longaker, M. T. (2022) · Cell Stem Cell · doi:10.1016/j.stem.2022.07.006 · Cited by 795
Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis
Schwabe, R. F., Tabas, I., & Pajvani, U. B. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.311 · Cited by 671
Cellular mechanotransduction in health and diseases: from molecular mechanism to therapeutic targets
Di, X., Gao, X., Peng, L., Ai, J., Jin, X., Qi, S., Li, H., Wang, K., & Luo, D. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01501-9 · Cited by 622
Evasion of apoptosis by myofibroblasts: a hallmark of fibrotic diseases
Hinz, B., & Lagares, D. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0324-5 · Cited by 614
The Hippo Signaling Network and Its Biological Functions
Misra, J. R., & Irvine, K. D. (2018) · Annual Review of Genetics · doi:10.1146/annurev-genet-120417-031621 · Cited by 497
Liver fibrosis: Direct antifibrotic agents and targeted therapies
Schuppan, D., Ashfaq-Khan, M., Yang, A. T., & Kim, Y. O. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.04.006 · Cited by 435
Tschumperlin, D. J., Ligresti, G., Hilscher, M. B., & Shah, V. H. (2018) · Journal of Clinical Investigation · doi:10.1172/jci93561 · Cited by 330
Activation of YAP attenuates hepatic damage and fibrosis in liver ischemia-reperfusion injury
Liu, Y., Lu, T., Zhang, C., Xu, J., Xue, Z., Busuttil, R. W., Xu, N., Xia, Q., Kupiec-Weglinski, J. W., & Ji, H. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.05.029 · Cited by 278
Hepatic Stellate Cell-Macrophage Crosstalk in Liver Fibrosis and Carcinogenesis
Matsuda, M., & Seki, E. (2020) · Seminars in Liver Disease · doi:10.1055/s-0040-1708876 · Cited by 189
Mechanical regulation of myofibroblast phenoconversion and collagen contraction
Hinz, B., McCulloch, C. A., & Coelho, N. M. (2019) · Experimental Cell Research · doi:10.1016/j.yexcr.2019.03.027 · Cited by 182
Implant Fibrosis and the Underappreciated Role of Myofibroblasts in the Foreign Body Reaction
Noskovicova, N., Hinz, B., & Pakshir, P. (2021) · Cells · doi:10.3390/cells10071794 · Cited by 184
Feng, Y., Liang, Y., Zhu, X., Wang, M., Gui, Y., Lu, Q., Gu, M., Xue, X., Sun, X., He, W., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.005457 · Cited by 152
Targeting acid ceramidase inhibits YAP/TAZ signaling to reduce fibrosis in mice
Alsamman, S., Christenson, S. A., Yu, A., Ayad, N. M. E., Mooring, M. S., Segal, J. M., Hu, J. K.-H., Schaub, J. R., Ho, S. S., Rao, V., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay8798 · Cited by 122
Mesenchymal stem cells in fibrotic diseases—the two sides of the same coin
Qin, L., Liu, N., Bao, C.-L.-M., Yang, D.-Z., Ma, G.-X., Yi, W.-H., Xiao, G.-Z., & Cao, H.-L. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00952-0 · Cited by 114
Maladaptive regeneration - the reawakening of developmental pathways in NASH and fibrosis
Zhu, C., Tabas, I., Schwabe, R. F., & Pajvani, U. B. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00365-6 · Cited by 112
Mederacke, I., Filliol, A., Affo, S., Nair, A., Hernandez, C., Sun, Q., Hamberger, F., Brundu, F., Chen, Y., Ravichandra, A., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abe5795 · Cited by 103
Self-citationMiranda, M. Z., Bialik, J. F., Speight, P., Dan, Q., Yeung, T., Szászi, K., Pedersen, S. F., & Kapus, A. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.780502 · Cited by 103
Myofibroblast YAP/TAZ activation is a key step in organ fibrogenesis
He, X., Tolosa, M. F., Zhang, T., Goru, S. K., Ulloa Severino, L., Misra, P. S., McEvoy, C. M., Caldwell, L., Szeto, S. G., Gao, F., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.146243 · Cited by 106
Transcriptional regulation of Hepatic Stellate Cell activation in NASH
Marcher, A.-B., Bendixen, S. M., Terkelsen, M. K., Hohmann, S. S., Hansen, M. H., Larsen, B. D., Mandrup, S., Dimke, H., Detlefsen, S., & Ravnskjaer, K. (2019) · Scientific Reports · doi:10.1038/s41598-019-39112-6 · Cited by 95
Ezzo, M., Spindler, K., Wang, J. B., Lee, D., Pecoraro, G., Cowen, J., Pakshir, P., & Hinz, B. (2024) · Science Advances · doi:10.1126/sciadv.adp4726 · Cited by 82
Guo, Q., Furuta, K., Islam, S., Caporarello, N., Kostallari, E., Dielis, K., Tschumperlin, D. J., Hirsova, P., & Ibrahim, S. H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.983255 · Cited by 73
Mechanotransduction in Liver Diseases
Kang, N. (2020) · Seminars in Liver Disease · doi:10.1055/s-0039-3399502 · Cited by 57
Profibrotic epithelial phenotype: a central role for MRTF and TAZ
Bialik, J. F., Ding, M., Speight, P., Dan, Q., Miranda, M. Z., Di Ciano-Oliveira, C., Kofler, M. M., Rotstein, O. D., Pedersen, S. F., Szászi, K., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-40764-7 · Cited by 41
Zhao, W., Yuan, W., Dong, T., Qi, W., Feng, Z., Li, C., & Sun, Y. (2025) · Communications Biology · doi:10.1038/s42003-025-08160-2 · Cited by 16
Metadata
- Authors
- Martin, K., Pritchett, J., Llewellyn, J., Mullan, A. F., Athwal, V. S., Dobie, R., Harvey, E., Zeef, L., Farrow, S., Streuli, C., Henderson, N. C., Friedman, S. L., Hanley, N. A., & Piper Hanley, K.
- Venue
- Nature Communications
- Published
- 2016-08-18
- Volume
- 7
- Issue
- 1
- Pages
- 12502-12502
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W2508686416
- Cited by
- 219
- References
- 10
- FWCI
- 10.93
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.